Cash Position
The company has -3.0 months of cash left based on the quarterly cash burn of $1.66 M and estimated current cash of $-1.65 M
Commentary on Financial Condition
Coeptis Therapeutics Holdings, Inc. is currently facing financial challenges, with minimal revenue generation and a significant decrease in cash from $1,469,134 in 2023 to $532,885 in 2024. The company has been focusing on product development and strategic partnerships, but it does not expect to generate significant revenue in the near term. Operating expenses have decreased, primarily due to reduced research and development costs, but interest expenses have increased, indicating reliance on debt. The company plans to improve liquidity and fund operations through equity capital financings in 2025., Filed At: 2025-03-27
Former Symbols
Nasdaq Compliance
Date
Deficiency
Market
Status
Notes
Previous Splits
Date
Split
12/31/2024
20 to 1
8/6/2020
40000 to 1
Pending Offering
Title | Details | Offering Amt | Shr Amt | Share Price | Warrants | Bank | Date | Type | |
|---|---|---|---|---|---|---|---|---|---|
INITIAL REGISTRATION FOR OFFERING | WITHDRAWN | - | - | - | - | - | Feb 3, 2022 | S-1 | |
1-A OFFERING | N/A | $12.00 M | 1.26 M | $80.00 | - | Turner, Stone & Company, LLP | Nov 18, 2021 | 1-A | |
1-A OFFERING | The shares were exchanged for acquired corporation pursuant to a merger agreement. | $12.00 M | 1.26 M | - | - | Turner, Stone & Company, LLP | Nov 18, 2021 | 1-A |
Warrants
Title | Registered | Remaining Warrants | Ex Price | Cost Basis | Total Warrants | Owners | Bank | Price Protection | Details | Exercisable Date | Expiration Date | Filed Date | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
February 2024 - Pre-Funded Warrants | Not Registered | - | $0.20 | 0.6 | 200,000 | N/A | Customary Anti-Dilution | - | - | Feb 8, 2024 | |||
December 2023 - Pre-Funded Warrants | Not Registered | - | $0.20 | 1 | 60,000 | N/A | Customary Anti-Dilution | - | - | Dec 28, 2023 | |||
October 2023 -Series A Warrants | Registered | 100,000 | $27.20 | - | 100,000 | AG Bio, AMLS, Armistice, Biofin, Leonite | Customary Anti-Dilution | - | - | Oct 26, 2023 | |||
October 2023 -Series B Warrants | Registered | 100,000 | $27.20 | - | 100,000 | AG Bio, AMLS, Armistice, Biofin, Leonite | Customary Anti-Dilution | - | - | Oct 26, 2023 | |||
June 2023 -Series A Warrants | Registered | 153,125 | $27.20 | - | 153,125 | David Mehalick, Daniel Yerace, Christopher Calise, Tara DeSilva, Philippe Deschamps, Christopher Cochran, Gene Salkind, Brian Cogley, Christine Sheehy, Lisa Pharma LLC, Lena Pharma LLC | Customary Anti-Dilution | - | - | Jun 16, 2023 | |||
June 2023 -Series B Warrants | Registered | 153,125 | $27.20 | - | 153,125 | David Mehalick, Daniel Yerace, Christopher Calise, Tara DeSilva, Philippe Deschamps, Christopher Cochran, Gene Salkind, Brian Cogley, Christine Sheehy, Lisa Pharma LLC, Lena Pharma LLC | Customary Anti-Dilution | - | - | Jun 16, 2023 | |||
June 2023 - Pre-Funded Warrants | Registered | 37,250 | $0.20 | 1 | 67,500 | David Mehalick, Daniel Yerace, Christopher Calise, Tara DeSilva, Philippe Deschamps, Christopher Cochran, Gene Salkind, Brian Cogley, Christine Sheehy, Lisa Pharma LLC, Lena Pharma LLC | Customary Anti-Dilution | - | - | Jun 16, 2023 | |||
October 2022 - Warrants | Not Registered | 187,500 | $230.00 | - | 187,500 | N/A | Customary Anti-Dilution | - | - | Oct 31, 2022 | |||
October 2022 - Warrants | Not Registered | 187,500 | $230.00 | - | 187,500 | N/A | Customary Anti-Dilution | - | - | Oct 31, 2022 |
Convertibles
Title | Registered | Shares Remaining | Cv Price | $ Amt Remaining | Total $ Amt | Owners | Bank | Price Protection | Details | Convertible Date | Maturity Date | Filed Date | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
January 2025 Convertible Note | Not Registered | 55,000 | $20.00 | $1,100,000.00 | $1,100,000.00 | YA II PN, LTD | Variable Rate | Conversion price is the lower of 20.00 or 95% of the lowest daily VWAP during the 5 consecutive trading days prior to conversion but not lower than $1.00. | - | Dec 31, 2025 | Jan 17, 2025 | ||
November 2024 - - Convertible Promissory Note - Yorkville may convert the Yorkville Note into shares of Common Stock at any time at a conversion price equal to the lower of (i) $1.00 (the “Fixed Price”) or (ii) a price per share equal to 95% of the lowest daily VWAP during the 5 consecutive trading days immediately prior to the conversion date of the Yorkville Note (the “Variable Price”), but which Variable Price shall not be lower than a floor price of $0.04 (the “Floor Price”). | Registered | 65,238 | $20.00 | $1,304,758.00 | $20,000,000.00 | YA II PN, LTD | Yorkville can convert the Yorkville Note into Common Stock at the lower of: (i) $20 (Fixed Price) or (ii) 95% of the lowest daily VWAP over the 5 trading days before conversion (Variable Price), but not below $0.04 (Floor Price). | - | Nov 1, 2025 | Nov 6, 2024 | |||
June 2024 - Convertible Preferred | Not Registered | 537,500 | $8.00 | $4,300,000.00 | $4,300,000.00 | CJC Investment Trust | Customary Anti-Dilution | - | - | Jun 14, 2024 |
Completed Offerings
Title | Offering Amt | Shr Amt | Share Price | Warrants | Bank | Owners | Date | Type | |
|---|---|---|---|---|---|---|---|---|---|
NEW EQUITY LINE | $20.00 M | - | - | - | - | - | Nov 6, 2024 | 8-K | |
PRIVATE PLACEMENT | $4.30 M | 537.50 k | $8.00 | 0.00 | - | CJC Investment Trust | Jun 14, 2024 | 8-K | |
PRIVATE PLACEMENT | $2.00 M | 100.00 k | $20.00 | 200.00 k | Ladenburg Thalmann | AG Bio, AMLS, Armistice, Biofin, Leonite | Oct 24, 2023 | 8-K | |
REGISTERED OFFERING (UNDERWRITTEN) | $3.50 M | 175.00 k | $20.00 | 306.25 k | Ladenburg Thalmann | Armistice | Jun 14, 2023 | 8-K |